Adverum Biotechnologies, Inc.

LSE:0HA3 Stock Report

Market Cap: US$157.3m

Adverum Biotechnologies Valuation

Is 0HA3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0HA3's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0HA3's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HA3?

Key metric: As 0HA3 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0HA3. This is calculated by dividing 0HA3's market cap by their current book value.
What is 0HA3's PB Ratio?
PB Ratio1x
BookUS$144.12m
Market CapUS$157.27m

Price to Book Ratio vs Peers

How does 0HA3's PB Ratio compare to its peers?

The above table shows the PB ratio for 0HA3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average40x
PRTC PureTech Health
1.7x-13.0%UK£415.6m
FARN Faron Pharmaceuticals Oy
139.3x17.3%UK£159.6m
BVXP Bioventix
17.1xn/aUK£204.9m
ETX e-therapeutics
1.9xn/aUK£52.6m
0HA3 Adverum Biotechnologies
1x-16.9%US$157.3m

Price-To-Book vs Peers: 0HA3 is good value based on its Price-To-Book Ratio (1x) compared to the peer average (40x).

Price to Book Ratio vs Industry

How does 0HA3's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.30m
VAL ValiRx
0.5xn/aUS$2.39m
No more companies available in this PB range
0HA3 1.0xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0HA3 is good value based on its Price-To-Book Ratio (1x) compared to the UK Biotechs industry average (3x).

Price to Book Ratio vs Fair Ratio

What is 0HA3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HA3 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0HA3's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HA3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.41
US$29.71
+301.0%
36.1%US$40.00US$10.00n/a7
Nov ’25US$7.33
US$30.00
+309.3%
34.0%US$40.00US$12.00n/a7
Oct ’25US$6.60
US$30.00
+354.7%
34.0%US$40.00US$12.00n/a7
Sep ’25US$6.79
US$30.00
+342.2%
34.0%US$40.00US$12.00n/a7
Aug ’25US$7.29
US$33.57
+360.3%
40.7%US$60.00US$15.00n/a7
Jul ’25US$6.79
US$33.86
+399.0%
38.4%US$60.00US$20.00n/a7
Jun ’25US$8.32
US$35.33
+324.9%
38.2%US$60.00US$20.00n/a6
May ’25US$10.03
US$35.33
+252.4%
38.2%US$60.00US$20.00n/a6
Apr ’25US$14.15
US$40.00
+182.7%
31.6%US$60.00US$20.00n/a5
Mar ’25US$19.61
US$42.00
+114.1%
23.3%US$60.00US$30.00n/a5
Feb ’25US$11.34
US$38.00
+235.1%
34.9%US$60.00US$20.00n/a5
Jan ’25US$7.52
US$38.00
+405.3%
34.9%US$60.00US$20.00n/a5
Dec ’24US$8.05
US$38.00
+372.2%
34.9%US$60.00US$20.00n/a5
Nov ’24US$9.25
US$38.00
+310.9%
34.9%US$60.00US$20.00US$7.335
Oct ’24US$15.60
US$42.50
+172.4%
25.6%US$60.00US$30.00US$6.604
Sep ’24US$17.71
US$42.50
+140.0%
25.6%US$60.00US$30.00US$6.794
Aug ’24US$21.98
US$43.33
+97.1%
28.8%US$60.00US$30.00US$7.293
Jul ’24US$15.70
US$40.00
+154.8%
35.4%US$60.00US$30.00US$6.793
Jun ’24US$11.90
US$40.00
+236.1%
35.4%US$60.00US$30.00US$8.323
May ’24US$8.41
US$32.50
+286.6%
50.4%US$60.00US$20.00US$10.034
Apr ’24US$7.90
US$32.50
+311.4%
50.4%US$60.00US$20.00US$14.154
Mar ’24US$7.20
US$36.67
+409.2%
46.4%US$60.00US$20.00US$19.613
Feb ’24US$6.70
US$36.67
+447.3%
46.4%US$60.00US$20.00US$11.343
Jan ’24US$5.90
US$36.67
+521.5%
46.4%US$60.00US$20.00US$7.523
Dec ’23US$6.67
US$36.67
+449.6%
46.4%US$60.00US$20.00US$8.053
Nov ’23US$9.00
US$45.00
+399.9%
32.7%US$60.00US$25.00US$9.253

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€826.3m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€46.95

7D

-2.9%

1Y

-26.3%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€65.15

7D

-1.8%

1Y

30.4%

hVIVO

UK£182.0m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.27

7D

-2.2%

1Y

44.6%